Lung-protective effects of the metalloporphyrinic peroxynitrite decomposition catalyst WW-85 in interleukin-2 induced toxicity

Biochemical and Biophysical Research Communications

Volumn 377, Issue 3, 2008, Pages 786-791

  Maybauer, Dirk M ^a   Maybauer, Marc O ^a   Szabó, Csaba ^a   Westphal, Martin ^c   Traber, Lillian D ^a   Enkhbaatar, Perenlei ^a   Murthy, Kanneganti G K ^d   Nakano, Yoshimitsu ^a   Salzman, Andrew L ^d   Herndon, David N ^b   Traber, Daniel L ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d INOTEK CORPORATION   (United States)

Author keywords

Cancer therapy; Lung lymph flow; Nitric oxide; Transvascular fluid flux; Vascular leakage

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; METALLOPORPHYRIN; PEROXYNITRITE; RECOMBINANT INTERLEUKIN 2; RESPIRATORY TRACT AGENT; UNCLASSIFIED DRUG; WW 85;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYST; CONTINUOUS INFUSION; CONTROLLED STUDY; CORE TEMPERATURE; DECOMPOSITION; FEMALE; LIPID PEROXIDATION; LUNG FLUID; LUNG TOXICITY; NONHUMAN; PRIORITY JOURNAL; PULMONARY VASCULAR LEAKAGE SYNDROME; SHEEP; TACHYCARDIA; VASCULAR DISEASE;

ANIMALS; CAPILLARY LEAK SYNDROME; CAPILLARY PERMEABILITY; CATALYSIS; HEMODYNAMICS; INTERLEUKIN-2; LUNG; LYMPH; MALONDIALDEHYDE; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PEROXIDASE; PEROXYNITROUS ACID; PULMONARY GAS EXCHANGE; RECOMBINANT PROTEINS; SHEEP; TYROSINE;

OVIS ARIES;

EID: 56049085330     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.10.066     Document Type: Article

References (35)

1. Herskind C., Fleckenstein K., Lohr J., Li C.Y., Wenz F., and Lohr F. Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis. Strahlenther. Onkol. 180 (2004) 187-193
2. Herskind C., Fleckenstein K., Lohr J., Li C.Y., Wenz F., and Lohr F. Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies. Strahlenther. Onkol. 180 (2004) 331-339
3. Waldmann T.A., Goldman C.K., Robb R.J., Depper J.M., Leonard W.J., Sharrow S.O., Bongiovanni K.F., Korsmeyer S.J., and Greene W.C. Expression of interleukin 2 receptors on activated human B cells. J. Exp. Med. 160 (1984) 1450-1466
4. Grimm E.A., and Wilson D.J. The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. Cell Immunol. 94 (1985) 568-578
5. Rosenberg S.A. The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann. Surg. 208 (1988) 121-135
6. Libra M., Talamini R., Crivellari D., Buonadonna A., Freschi A., Stefanovski P., Berretta M., De Cicco M., Balestreri L., Merlo A., Volpe R., Galligioni E., and Sorio R. Long-term survival in patients with metastatic renal cell carcinoma treated with continuous intravenous infusion of recombinant interleukin-2: the experience of a single institution. Tumori 89 (2003) 400-404
7. Murakami K., Privalle C., Enkhbaatar P., Shimoda K., Schmalstieg F.C., Deangelo J., Lee S., Traber L.D., and Traber D.L. Pyridoxalated haemoglobin polyoxyethylene conjugate, a nitric oxide scavenger, decreases dose-limiting hypotension associated with interleukin-2 (IL-2) therapy. Clin. Sci. (Lond.) 105 (2003) 629-635
8. Szabo C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Shock 6 (1996) 79-88
9. Westphal M., Morita N., Enkhbaatar P., Murakami K., Traber L., and Traber D.L. Carboxyhemoglobin formation following smoke inhalation injury in sheep is interrelated with pulmonary shunt fraction. Biochem. Biophys. Res. Commun. 311 (2003) 754-758
10. Westphal M., Morita N., Enkhbaatar P., Murakami K., Traber L., and Traber D.L. Acute effects of combined burn and smoke inhalation injury on carboxyhemoglobin formation, tissue oxygenation, and cardiac performance. Biochem. Biophys. Res. Commun. 317 (2004) 945-949
11. Staub N.C., Bland R.D., Brigham K.L., Demling R., Erdmann III A.J., and Woolverton W.C. Preparation of chronic lung lymph fistulas in sheep. J. Surg. Res. 19 (1975) 315-320
12. Maybauer M.O., Maybauer D.M., Fraser J.F., Traber L.D., Westphal M., Enkhbaatar P., Cox R.A., Huda R., Hawkins H.K., Morita N., Murakami K., Mizutani A., Herndon D.N., and Traber D.L. Recombinant human activated protein C improves pulmonary function in ovine acute lung injury following smoke inhalation injury and sepsis. Crit. Care Med. 34 (2006) 2432-2438
13. Shimoda K., Murakami K., Enkhbaatar P., Traber L.D., Cox R.A., Hawkins H.K., Schmalstieg F.C., Komjati K., Mabley J.G., Szabo C., Salzman A.L., and Traber D.L. Effect of poly(ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. Am. J. Physiol. Lung Cell Mol. Physiol. 285 (2003) L240-L249
14. Asfar P., Hauser B., Radermacher P., and Matejovic M. Catecholamines and vasopressin during critical illness. Crit. Care Clin. 22 (2006) 131-138
15. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 271 (1996) C1424-C1437
16. Sampson J.B., Ye Y., Rosen H., and Beckman J.S. Myeloperoxidase and horseradish peroxidase catalyze tyrosine nitration in proteins from nitrite and hydrogen peroxide. Arch. Biochem. Biophys. 356 (1998) 207-213
17. Eiserich J.P., Patel R.P., and O'Donnell V.B. Pathophysiology of nitric oxide and related species: free radical reactions and modification of biomolecules. Mol. Aspects Med. 19 (1998) 221-357
18. Gaut J.P., Byun J., Tran H.D., Lauber W.M., Carroll J.A., Hotchkiss R.S., Belaaouaj A., and Heinecke J.W. Myeloperoxidase produces nitrating oxidants in vivo. J. Clin. Invest. 109 (2002) 1311-1319
19. Hanazawa T., Kharitonov S.A., and Barnes P.J. Increased nitrotyrosine in exhaled breath condensate of patients with asthma. Am. J. Respir. Crit. Care Med. 164 (2000) 1273-1276
20. Szabolcs M.J., Sun J., Ma N., Albala A., Sciacca R.R., Philips G.B., Parkinson J., Edwards N., and Cannon P.J. Effects of selective inhibitors of nitric oxide synthase-2 dimerization on acute cardiac allograft rejection. Circulation 106 18 (2002) 2392-2396
21. Szabolcs M.J., Ma N., Athan E., Zhong J., Ming M., Sciacca R.R., Husemann J., Albala A., and Cannon P.J. Acute cardiac allograft rejection in nitric oxide synthase-2(-/-) and nitric oxide synthase-2(+/+) mice: effects of cellular chimeras on myocardial inflammation and cardiomyocyte damage and apoptosis. Circulation 103 (2001) 2514-2520
22. Pieper G.M., Nilakantan V., Chen M., Zhou J., Khanna A.K., Henderson Jr. J.D., Johnson C.P., Roza A.M., and Szabo C. Protective mechanisms of a metalloporphyrinic peroxynitrite decomposition catalyst, WW85, in rat cardiac transplants. J. Pharmacol. Exp. Ther. 314 (2005) 53-60
23. Lancel S., Tissier S., Mordon S., Marechal X., Depontieu F., Scherpereel A., Chopin C., and Neviere R. Peroxynitrite decomposition catalysts prevent myocardial dysfunction and inflammation in endotoxemic rats. J. Am. Coll. Cardiol. 43 (2004) 2348-2358
24. Naidu B.V., Fraga C., Salzman A.L., Szabo C., Verrier E.D., and Mulligan M.S. Critical role of reactive nitrogen species in lung ischemia-reperfusion injury. J. Heart Lung Transplant. 22 (2003) 784-793
25. Virag L., and Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54 (2002) 375-429
26. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol. Lett. 140-141 (2003) 105-112
27. Szabo C. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect. 15 (2002) 197-205
28. Szabo G., Bahrle S., Stumpf N., Sonnenberg K., Szabo E.E., Pacher P., Csont T., Schulz R., Dengler T.J., Liaudet L., Jagtap P.G., Southan G.J., Vahl C.F., Hagl S., and Szabo C. Poly(ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ. Res. 90 (2002) 100-106
29. Liu Y., Son N.H., Szabolcs M.J., Ma N., Sciacca R.R., Albala A., Edwards N., and Cannon P.J. Effects of inhibition of poly(adenosine diphosphate-ribose) synthase on acute cardiac allograft rejection. Transplantation 78 (2004) 668-674
30. Pacher P., Vaslin A., Benko R., Mabley J.G., Liaudet L., Hasko G., Marton A., Batkai S., Kollai M., and Szabo C. A new potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging. J. Pharmacol. Exp. Ther. 311 (2004) 485-491
31. Pacher P., Liaudet L., Mabley J., Komjati K., and Szabo C. Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J. Am. Coll. Cardiol. 40 (2002) 1006-1016
32. Pacher P., Mabley J.G., Soriano F.G., Liaudet L., and Szabo C. Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int. J. Mol. Med. 9 (2002) 659-664
33. Pacher P., Mabley J.G., Soriano F.G., Liaudet L., Komjati K., and Szabo C. Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation. Br. J. Pharmacol. 135 (2002) 1347-1350
34. Pacher P., Liaudet L., Bai P., Virag L., Mabley J.G., Hasko G., and Szabo C. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J. Pharmacol. Exp. Ther. 300 (2002) 862-867
35. Naidu B.V., Farivar A.S., Woolley S.M., Fraga C., Salzman A.L., Szabo C., Groves J.T., and Mulligan M.S. Enhanced peroxynitrite decomposition protects against experimental obliterative bronchiolitis. Exp. Mol. Pathol. 75 (2003) 12-17